文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

接受玻璃体腔化疗的视网膜母细胞瘤眼外扩散风险

Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy.
PubMed 文献 · JAMA Ophthalmol · 2017-01-01

这项回顾性队列研究纳入北美、南美、欧洲、以色列和中国10家视网膜母细胞瘤中心的655例患者,共704眼接受3553次玻璃体腔化疗注射(3201次美法仑、335次托泊替康、17次甲氨蝶呤),未发生与既往注射相关的眼外肿瘤事件;按3倍法则计算,每眼眼外事件发生比例为零,风险不高于0.08%的注射次数。

要点

  • 10家中心655例患者704眼共接受3553次玻璃体腔化疗注射,未发生与注射相关的眼外肿瘤事件。
  • 按3倍法则计算,眼外扩散风险不高于0.08%的注射次数。
  • 全部10家中心均使用至少2种推测性预防注射方法。

核心结论

  • 在使用至少2种推测性预防安全方法的情况下,未发生肿瘤眼外扩散事件,按3倍法则风险不高于0.08%的注射次数。

研究设计与样本

  • 回顾性队列研究,纳入北美、南美、欧洲、以色列和中国10家视网膜母细胞瘤中心的655例患者704眼,1999年2月1日至2017年2月28日期间接受玻璃体腔化疗注射。

主要发现

  • 共实施3553次玻璃体腔化疗注射(美法仑盐酸盐3201次、托泊替康盐酸盐335次、甲氨蝶呤钠17次),患者初次注射时平均(SD)年龄31.6(11.6)个月,男性348例(53.1%)。
  • 未发生与既往玻璃体腔注射相关的眼外肿瘤事件,计算得每眼眼外事件发生比例为零。
  • 按3倍法则,风险不高于0.08%的注射次数。
  • 全部10家中心均使用至少2种推测性预防注射方法(降低眼内压、冷冻治疗、眼表冲洗、注射部位超声生物显微镜监测、结膜下化疗药物沉积)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The risk of extraocular extension from injecting chemotherapy into eyes with retinoblastoma is minimally understood; however, understanding this risk is important because of the increasing use of intravitreous chemotherapy. OBJECTIVE: To evaluate the risk of extraocular extension in eyes with retinoblastoma that have received intravitreous chemotherapy injections. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study was performed in 655 patients at 10 retinoblastoma centers in North and South American, European, Israeli, and Chinese centers. Physicians at the retinoblastoma centers administered more than 120 intravitreous chemotherapy injections in eyes with retinoblastoma from February 1, 1999, through February 28, 2017. MAIN OUTCOMES AND MEASURES: Risk of extraocular extension with secondary observational variables, including injection and precautionary techniques. RESULTS: A total of 3553 intravitreous chemotherapy injections (3201 melphalan hydrochloride, 335 topotecan hydrochloride, and 17 methotrexate sodium) were administered to 704 eyes in 655 patients with retinoblastoma (mean [SD] age of patients at the time of the initial injections, 31.6 [11.6] months; 348 male [53.1%]). There were no extraocular tumor events related to prior intravitreous injections. This finding resulted in a calculated proportion of zero extraocular events per eye. According to the rule of 3, the risk is no greater than 0.08% injections. All 10 centers included in this study used at least 2 presumed precautionary injection methods (lowering of intraocular pressure, cryotherapy, ocular surface irrigation, ultrasonic biomicroscopy surveillance of the injection site, and subconjunctival chemotherapy deposition). CONCLUSIONS AND RELEVANCE: With use of at least 2 presumed precautionary safety methods, no extraocular extension of tumor events occurred. According to the rule of 3, this finding suggests that the risk is no greater than 0.08% injections.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Francis JH, Abramson DH, Ji X, et al. Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy. JAMA Ophthalmol. 2017. PMID: 29098285. doi:10.1001/jamaophthalmol.2017.4600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。